ImmCelz™
Type 1 Diabetes
Key Facts
About Creative Medical Technology Holdings
Creative Medical Technology Holdings is a US-based regenerative medicine and immunotherapy company with a mission to improve patient lives through innovative autologous cell therapies. Its core strategy leverages two disruptive platforms: the ImmCelz™ Supercharged Autologous Immunotherapy platform for modulating immune disorders and a Rapid Autologous Stem Cell platform for orthopedic and degenerative conditions. Recent achievements include an FDA Orphan Drug Designation for ImmCelz™ in Type 1 Diabetes and a Notice of Allowance for a key patent, positioning the company in sizable markets with a potentially differentiated clinical approach.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |